Rodman & Renshaw downgraded G1 Therapeutics to Neutral from Buy with a $7.15 price target after the company entered into a merger agreement under which Pharmacosmos will acquire all outstanding shares of G1 common stock for $7.15 per share in cash.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTHX:
- Pharmacosmos Group to Acquire G1 Therapeutics
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
- G1 Therapeutics added to Russell 2000, 3000 Indexes
- G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue